Stem cells for heart failure
Friday, 06 June, 2008
Mesoblast (ASX: MSB) will soon launch phase II trials into congestive heart failure, the company said.
The trials will be conducted by its US-based sister company Angioblast Systems.
The US FDA recently granted the companies permission to perform clinical trials using its adult stem cell-based treatment.
45 clients suffering from congestive heart failure will be given allogeneic stem cells, while 15 will be given a placebo.
The stem cells will be injected directly into the patients' hearts through a cardiac catheter.
In pilot trials conducted in Australia, a similar injection method using the patients' own cells was shown to improve heart muscle function and reduce the risk of heart failure. Mesoblast said using healthy stem cells will improve the results even further.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
